Literature DB >> 12445680

p53 Codon 72 polymorphism and urothelial cancer risk.

Yoshiki Kuroda1, Hiromasa Tsukino, Hiroyuki Nakao, Hirohisa Imai, Takahiko Katoh.   

Abstract

The p53 tumor suppressor gene is often mutated in various human cancers. Recently, the p53 codon 72 polymorphism has been extensively studied to determine the risk factors responsible for cancer formation. We investigated the genotype distribution of the p53 codon 72 polymorphism in 112 male urothelial cancer cases and 175 male unrelated non-cancer controls. The allelic frequencies in Japanese non-cancer controls were 0.58 (Arg) and 0.42 (Pro). There was no significant difference in the three genotype frequencies (Arg/Arg, Arg/Pro, Pro/Pro) of the p53 codon 72 between the urothelial cancer cases and the controls. However, stratifying by smoking status, we found that the frequency of the Pro/Pro genotype for smokers was significantly more than that for never-smokers (odds ratio (OR)=2.28, 95% confidence interval (95%CI)=1.12-4.66). Furthermore, we divided smoking status (pack-years) into quartiles (<20, 20-40, 40-60, >60). OR (Pro/Pro vs. Arg/Arg) for the lighter smokers (<20 pack-years) was higher than in other groups (OR=6.83). Our results suggest that the Pro/Pro genotype of the p53 codon 72 polymorphism increases the risk of urothelial cancer in smokers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12445680     DOI: 10.1016/s0304-3835(02)00518-9

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population.

Authors:  Zhong-Zheng Zhu; Wen-Ming Cong; Shu-Fang Liu; Hui Dong; Guan-Shan Zhu; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

2.  Quantitative assessment of the association between TP53 Arg72Pro polymorphism and bladder cancer risk.

Authors:  Zhi-Hong Liu; Er-Dun Bao
Journal:  Mol Biol Rep       Date:  2012-11-27       Impact factor: 2.316

3.  XPC intron11 C/A polymorphism as a risk factor for prostate cancer.

Authors:  Yoshihiro Yoshino; Shouhei Takeuchi; Takahiko Katoh; Yoshiki Kuroda
Journal:  Environ Health Prev Med       Date:  2016-01-08       Impact factor: 3.674

4.  Association between p53 codon 72 genetic polymorphism and tobacco use and lung cancer risk.

Authors:  Dante D Cáceres; Luis A Quiñones; Jane C Schroeder; Leonel D Gil; Carlos E Irarrázabal
Journal:  Lung       Date:  2009-01-07       Impact factor: 2.584

5.  Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.

Authors:  Yasuki Hori; Katsuyuki Miyabe; Michihiro Yoshida; Takahiro Nakazawa; Kazuki Hayashi; Itaru Naitoh; Shuya Shimizu; Hiromu Kondo; Yuji Nishi; Shuichiro Umemura; Akihisa Kato; Hirotaka Ohara; Hiroshi Inagaki; Takashi Joh
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

6.  Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.

Authors:  Ten-i Godai; Tetsuji Suda; Nobuhiro Sugano; Kazuhito Tsuchida; Manabu Shiozawa; Hironobu Sekiguchi; Akiko Sekiyama; Mitsuyo Yoshihara; Shoichi Matsukuma; Yuji Sakuma; Eiju Tsuchiya; Yoichi Kameda; Makoto Akaike; Yohei Miyagi
Journal:  BMC Cancer       Date:  2009-12-02       Impact factor: 4.430

7.  Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir.

Authors:  Arshad A Pandith; Nighat P Khan; Nargis Rashid; Niyaz Azad; Inam Zaroo; Adil Hafiz; Mushtaq A Siddiqi
Journal:  Tumour Biol       Date:  2012-01-17

8.  TP53 codon 72 Gene Polymorphism Paradox in Associated with Various Carcinoma Incidences, Invasiveness and Chemotherapy Responses.

Authors:  Hung-Yu Lin; Chun-Hsiung Huang; Wen-Jen Wu; Li-Ching Chang; For-Wey Lung
Journal:  Int J Biomed Sci       Date:  2008-12

9.  In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.

Authors:  Isrid Sturm; Andrew G Bosanquet; Michael Hummel; Bernd Dörken; Peter T Daniel
Journal:  BMC Cancer       Date:  2005-08-18       Impact factor: 4.430

10.  Response to microtubule-interacting agents in primary epithelial ovarian cancer cells.

Authors:  Ilenia Pellicciotta; Chia-Ping Huang Yang; Charis A Venditti; Gary L Goldberg; Shohreh Shahabi
Journal:  Cancer Cell Int       Date:  2013-04-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.